State Street Corp Buys 81,057 Shares of Hologic, Inc. (NASDAQ:HOLX)

State Street Corp grew its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 0.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,409,327 shares of the medical equipment provider's stock after acquiring an additional 81,057 shares during the period. State Street Corp owned 4.48% of Hologic worth $847,944,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Cetera Investment Advisers lifted its holdings in Hologic by 188.9% during the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider's stock valued at $1,595,000 after purchasing an additional 13,380 shares during the last quarter. Cetera Advisors LLC boosted its holdings in shares of Hologic by 144.8% during the 1st quarter. Cetera Advisors LLC now owns 8,800 shares of the medical equipment provider's stock worth $686,000 after buying an additional 5,205 shares during the period. CWM LLC grew its stake in Hologic by 4.1% in the 2nd quarter. CWM LLC now owns 9,638 shares of the medical equipment provider's stock valued at $716,000 after buying an additional 382 shares during the last quarter. Czech National Bank raised its holdings in Hologic by 7.7% in the 2nd quarter. Czech National Bank now owns 44,473 shares of the medical equipment provider's stock valued at $3,302,000 after acquiring an additional 3,172 shares during the period. Finally, Sequoia Financial Advisors LLC lifted its position in Hologic by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider's stock worth $536,000 after acquiring an additional 165 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on HOLX shares. StockNews.com upgraded Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th. UBS Group boosted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Mizuho lowered their price target on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Royal Bank of Canada increased their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a research report on Tuesday, November 5th. Finally, Leerink Partners dropped their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, Hologic has a consensus rating of "Moderate Buy" and a consensus price target of $89.91.

Hologic Price Performance

HOLX traded down $0.66 on Friday, reaching $75.34. The stock had a trading volume of 1,356,780 shares, compared to its average volume of 1,560,994. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $17.10 billion, a price-to-earnings ratio of 22.62, a price-to-earnings-growth ratio of 2.42 and a beta of 0.96. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The firm has a 50-day moving average of $79.81 and a 200-day moving average of $78.54.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter last year, the business earned $0.89 EPS. The firm's quarterly revenue was up 4.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.75% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.